Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Country versus pharmaceutical company interests for hepatitis C treatment
Roy Lothan, Noa Gutman,
Dan Yamin
*
*
Corresponding author for this work
Department of Industrial Engineering
Research output
:
Contribution to journal
›
Article
›
peer-review
2
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Country versus pharmaceutical company interests for hepatitis C treatment'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Hepatitis C Virus
100%
Pharmaceutical Companies
100%
Hepatitis C Treatment
100%
Company Interest
100%
Treatment Strategy
50%
Israel
25%
Politicians
25%
Analytical Framework
25%
Game Model
25%
Treatment Options
25%
Liver Disease
25%
Successful Treatment
25%
Chronic Conditions
25%
Screening Strategy
25%
Healthcare Settings
25%
Health Burden
25%
Economic Burden
25%
Risk-sharing Agreements
25%
End-stage Liver Disease
25%
Sales Volume
25%
Hepatitis C Virus Screening
25%
Quantity Discount
25%
Fixed Pricing
25%
Citizen Utilities
25%
Economics, Econometrics and Finance
Pricing
100%
Risk-Sharing
100%
Price
100%
Immunology and Microbiology
Hepatitis C
100%
Hepatitis C Virus
100%